As filed with the Securities and Exchange Commission on July 25, 2025 Registration No. 333-286850 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDNMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Safe & Green Holdings Corp. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Delaware 5030 95-4463937 (I.R.S. Employer Identification Number) 990 Biscayne Blvd ...

Core Viewpoint - BrightSpring Health Services, Inc. (BTSG) is expected to report a year-over-year increase in earnings and revenues for the quarter ended June 2025, with a consensus EPS estimate of $0.19, reflecting a 90% increase, and revenues projected at $2.99 billion, up 9.4% from the previous year [1][3]. Earnings Expectations - The stock price may rise if the actual earnings exceed expectations in the upcoming report, scheduled for August 1, while a miss could lead to a decline [2]. - The consensus EPS estimate has been revised 3.68% higher in the last 30 days, indicating a positive reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative Earnings ESP reading indicates the likely deviation of actual earnings from the consensus estimate, with a positive reading being a strong predictor of an earnings beat [9][10]. - For BrightSpring, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -8.11%, suggesting a bearish outlook [12]. Historical Performance - BrightSpring has beaten consensus EPS estimates in two out of the last four quarters, with a notable surprise of +137.50% in the last reported quarter [14][15]. Industry Comparison - CVS Health, a competitor in the Zacks Medical Services industry, is expected to report an EPS of $1.47, reflecting a year-over-year decrease of 19.7%, with revenues projected at $93.72 billion, up 2.7% [20]. - CVS Health has a positive Earnings ESP of +2.06% and a Zacks Rank of 2, indicating a likely earnings beat, having surpassed consensus EPS estimates in the last four quarters [20][21].

Company Overview - AirSculpt Technologies, Inc. is an industry leader in premium body contouring procedures, focusing on next-generation treatments that optimize comfort and precision [3]. Financial Results Announcement - AirSculpt will report its second quarter 2025 financial results before the market opens on August 1, 2025, followed by a conference call at 8:30 a.m. Eastern Time on the same day [1]. Conference Call Details - The conference call can be accessed via a toll-free domestic number (1-877-407-9716) or an international number (1-201-493-6779) using the conference ID 13754561, with a live webcast available on the investor relations section of the AirSculpt website [2].

Core Viewpoint - CVS Health is expected to report a year-over-year decline in earnings despite an increase in revenues, with the actual results being crucial for stock price movement [1][2]. Earnings Expectations - CVS Health is projected to post quarterly earnings of $1.47 per share, reflecting a year-over-year decrease of 19.7% [3]. - Revenues are anticipated to reach $93.72 billion, which is a 2.7% increase from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised 0.55% higher in the last 30 days, indicating a slight bullish sentiment among analysts [4]. - The Most Accurate Estimate for CVS Health is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +2.06% [12]. Earnings Surprise Prediction - A positive Earnings ESP reading suggests a higher likelihood of an earnings beat, especially when combined with a Zacks Rank of 2 (Buy) [10][12]. - CVS Health has a Zacks Rank of 2, indicating a strong potential for beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, CVS Health exceeded the expected earnings of $1.71 per share by delivering $2.25, resulting in a surprise of +31.58% [13]. - Over the past four quarters, CVS Health has consistently beaten consensus EPS estimates [14]. Industry Context - In the Zacks Medical Services industry, Teladoc is expected to report a loss of $0.27 per share, with a year-over-year change of +3.6% [18]. - Teladoc's revenue is projected to be $620.91 million, down 3.4% from the previous year [18]. - The consensus EPS estimate for Teladoc has been revised down by 3.9% in the last 30 days, resulting in an Earnings ESP of -13.8% [19].

Group 1 - BioNTech SE Sponsored ADR (BNTX) is a notable stock within the Medical sector, which consists of 985 companies and ranks 8 in the Zacks Sector Rank [2] - The Zacks Rank system indicates that BNTX has a current ranking of 2 (Buy), suggesting a positive outlook based on earnings estimates and revisions [3] - BNTX's full-year earnings consensus estimate has increased by 36.6% in the past quarter, indicating improved analyst sentiment and a stronger earnings outlook [4] Group 2 - Year-to-date, BNTX has returned approximately 0.6%, outperforming the Medical sector average return of -3.1% [4] - In comparison, EUROFINS SCIENT (ERFSF) has shown a significant year-to-date return of 45.5%, with a consensus EPS estimate increase of 1% over the past three months [5] - BNTX belongs to the Medical - Biomedical and Genetics industry, which includes 493 companies and currently ranks 94 in the Zacks Industry Rank, with an average gain of 2% this year [6] Group 3 - EUROFINS SCIENT is part of the Medical Services industry, which has 58 stocks and ranks 96, with an average decline of -6% this year [7] - Both BNTX and EUROFINS SCIENT are highlighted as stocks to track for continued solid performance in the Medical sector [7]

Core Viewpoint - GeneDx Holdings Corp. is anticipated to report a year-over-year increase in earnings driven by higher revenues, with a consensus outlook suggesting a significant earnings surprise could impact its stock price in the near term [1][2]. Company Summary - The upcoming earnings report is expected to show quarterly earnings of $0.10 per share, reflecting a year-over-year increase of +190.9%. Revenues are projected to reach $84.7 million, which is a 20.1% increase from the same quarter last year [3]. - The consensus EPS estimate has been revised down by 7.81% over the last 30 days, indicating a reassessment by analysts regarding the company's earnings prospects [4]. - The Most Accurate Estimate for GeneDx Holdings is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +5.26%. The company currently holds a Zacks Rank of 2, suggesting a strong likelihood of beating the consensus EPS estimate [12]. Earnings Surprise History - In the last reported quarter, GeneDx Holdings was expected to post earnings of $0.11 per share but actually delivered earnings of $0.28, resulting in a surprise of +154.55%. The company has beaten consensus EPS estimates in each of the last four quarters [13][14]. Industry Context - In the Zacks Medical Services industry, Revvity is expected to report earnings of $1.14 per share for the quarter ended June 2025, indicating a year-over-year decline of -6.6%. Revenue for Revvity is expected to be $711.27 million, up 2.8% from the previous year [18]. - Revvity's consensus EPS estimate has remained unchanged over the last 30 days, but a higher Most Accurate Estimate has led to an Earnings ESP of +0.88%. This suggests Revvity is also likely to beat the consensus EPS estimate, having done so in each of the trailing four quarters [19].

Core Viewpoint - Danaher (DHR) reported quarterly earnings of $1.8 per share, exceeding the Zacks Consensus Estimate of $1.64 per share, and showing a year-over-year decrease from $1.72 per share [1] Financial Performance - The company achieved revenues of $5.94 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.71% and increasing from $5.74 billion year-over-year [2] - Over the last four quarters, Danaher has exceeded consensus EPS estimates three times and topped revenue estimates four times [2] Stock Performance - Danaher shares have declined approximately 18.1% since the beginning of the year, contrasting with the S&P 500's gain of 7.2% [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating expectations of underperformance in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.80 on revenues of $6.02 billion, and for the current fiscal year, it is $7.70 on revenues of $24.52 billion [7] - The trend of estimate revisions for Danaher was unfavorable prior to the earnings release, which may impact future stock performance [6] Industry Context - The Medical Services industry, to which Danaher belongs, is currently ranked in the bottom 39% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Company Overview - Revvity (RVTY) is anticipated to report a year-over-year decline in earnings of 6.6%, with expected earnings of $1.14 per share, while revenues are projected to increase by 2.8% to $711.27 million for the quarter ended June 2025 [3][12]. Earnings Expectations - The earnings report is scheduled for release on July 28, and the stock may experience upward movement if the reported figures exceed expectations; conversely, a miss could lead to a decline in stock price [2][12]. - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4]. Earnings Surprise Prediction - Revvity has an Earnings ESP of +0.88%, suggesting a higher Most Accurate Estimate compared to the Zacks Consensus Estimate, indicating a bullish outlook from analysts [12]. - The company has a Zacks Rank of 3, which, when combined with the positive Earnings ESP, suggests a likelihood of beating the consensus EPS estimate [12]. Historical Performance - Revvity has consistently beaten consensus EPS estimates in the past four quarters, with a notable surprise of +5.21% in the last reported quarter [13][14]. Industry Context - In comparison, Labcorp Holdings (LH), another player in the medical services industry, is expected to report earnings of $4.14 per share, reflecting a year-over-year increase of 5.1%, with revenues projected at $3.49 billion, up 8.3% [18]. - Labcorp's consensus EPS estimate has been revised down by 0.1% over the last 30 days, resulting in an Earnings ESP of -0.26%, making it challenging to predict a beat against the consensus EPS estimate [19].

Company Performance - Organon (OGN) shares decreased by 1.87% to $9.46, underperforming the S&P 500's slight loss of 0.01% on the same day [1] - Over the past month, Organon shares have declined by 2.43%, compared to a 1.59% loss in the Medical sector and a 5.37% gain in the S&P 500 [1] Upcoming Earnings - The upcoming earnings release is anticipated, with an expected EPS of $0.94, reflecting a 16.07% decrease from the same quarter last year [2] - Revenue is forecasted at $1.55 billion, indicating a 3.35% decline compared to the same quarter of the previous year [2] Fiscal Year Estimates - For the entire fiscal year, earnings are projected at $3.83 per share, representing a -6.81% change from the previous year [3] - Revenue for the fiscal year is estimated at $6.24 billion, showing a -2.48% change from the prior year [3] Analyst Estimates - Recent adjustments to analyst estimates for Organon reflect changing short-term business dynamics, with positive revisions indicating analysts' confidence in performance [4] - The Zacks Rank system, which incorporates estimate changes, suggests a correlation between these revisions and stock price performance [5] Zacks Rank and Valuation - Organon currently holds a Zacks Rank of 2 (Buy), with a 0.55% increase in the consensus EPS estimate over the past month [6] - The company is trading at a Forward P/E ratio of 2.52, significantly lower than the industry average of 15.4, indicating a discount [7] - Organon has a PEG ratio of 0.96, compared to the industry average of 1.52, suggesting favorable valuation relative to growth expectations [7] Industry Context - The Medical Services industry, part of the Medical sector, has a Zacks Industry Rank of 90, placing it in the top 37% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]

Core Insights - Fangzhou Inc. has signed a Memorandum of Understanding with Novo Nordisk to collaborate on managing chronic diseases like diabetes and obesity using AI and innovative healthcare solutions [1][3][4] Company Overview - Fangzhou Inc. is a leading online chronic disease management platform in China, with 49.2 million registered users and 223,000 physicians as of December 31, 2024 [5] Collaboration Details - The partnership aims to leverage Novo Nordisk's expertise in diabetes and obesity treatment alongside Fangzhou's smart healthcare ecosystem to create a comprehensive health management service [3][4] - The collaboration will focus on medication guidance, reminders, efficacy tracking, and health education, shifting from a "disease-centered" to a "health-centered" model [3][4] Future Goals - Both companies aim to enhance public awareness of diabetes and obesity and implement early screening, diagnosis, and treatment within smart healthcare environments [4] - The partnership is expected to explore further innovative collaborations in the digital transformation of the medical industry, contributing to the "Healthy China 2030" strategic objectives [4]